Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Aug 21, 2023

BUY
$0.13 - $76.84 $0 - $537
7 New
7 $0
Q2 2022

Aug 21, 2023

BUY
$72.62 - $79.98 $508 - $559
7 New
7 $0
Q2 2022

Aug 02, 2022

BUY
$72.62 - $79.98 $508 - $559
7 New
7 $1,000
Q4 2020

Feb 17, 2023

SELL
$57.74 - $65.43 $20,209 - $22,900
-350 Closed
0 $0
Q1 2020

Sep 05, 2023

BUY
$46.4 - $67.43 $16,240 - $23,600
350 New
350 $19,000
Q1 2020

Feb 17, 2023

BUY
$46.4 - $67.43 $15,915 - $23,128
343 Added 4900.0%
350 $20,000
Q1 2019

Sep 01, 2023

BUY
$45.12 - $53.8 $15,792 - $18,830
350 New
350 $16,000
Q1 2019

Feb 13, 2023

BUY
$45.12 - $53.8 $15,476 - $18,453
343 Added 4900.0%
350 $17,000
Q4 2018

Feb 09, 2023

BUY
$48.76 - $63.23 $16,724 - $21,687
343 Added 4900.0%
350 $18,000
Q1 2018

Aug 29, 2023

BUY
$59.92 - $68.98 $20,972 - $24,143
350 New
350 $22.1 Million
Q2 2017

Aug 29, 2023

BUY
N/A
350 New
350 $19.5 Million
Q1 2017

Aug 29, 2023

BUY
N/A
350 New
350 $0
Q4 2016

Feb 09, 2023

BUY
N/A
343
350 $20,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Artemis Wealth Advisors, LLC Portfolio

Follow Artemis Wealth Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artemis Wealth Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Artemis Wealth Advisors, LLC with notifications on news.